Rasagiline
Top View
- Clinical Outcome Assessment (Coa) Compendium
- Pharmacological Aspects of the Neuroprotective Effects Of
- Methyldopa | Memorial Sloan Kettering Cancer Center
- Rasagiline ESCA: for the Treatment of Parkinson's Disease AREAS of RESPONSIBILITY for the SHARING of CARE
- A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations the PRESTO Study
- Sumatriptan (Injection) Medical Facts from Drugs.Com
- Activation of Tyrosine Kinase Receptor Signaling Pathway by Rasagiline
- Formulary and Program Updates Effective 8/1/18
- Download Leaflet View the Patient Leaflet in PDF Format
- Azilect Prescribing Information
- Treatment of Parkinson Disease with Motor Fluctuations And
- FDA Approved Labeling Text for NDA 021641/S-002/S-003/S-004/S-005/S-007/S-008/S-010 Dated 12/9/09
- Azilect) Reference Number: HIM.PA.89 Effective Date: 12.14 Last Review Date: 08.20 Line of Business: HIM Revision Log
- Sharp Health Plan 2020 Formulary List of Covered Prescription Drugs
- Neuroprotective Properties of Green Tea (Camellia Sinensis) in Parkinson’S Disease: a Review
- Hydride Abstraction As the Rate-Limiting Step of The
- Sembragiline: a Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’S Disease S
- Therapeutic Drug Class